Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MSFrexalimab high-dose arm obse...
- Reuters
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...
The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-25-20-30-00-2904145
- Bloomberg Citing Sources
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the...
